Premium
Compound heterozygous RPE65 mutations associated with an early onset autosomal recessive retinitis pigmentosa
Author(s) -
OwczarekLipska Marta,
Song Fei,
Jakšić Vesna,
Neidhardt John
Publication year - 2020
Publication title -
the journal of gene medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.689
H-Index - 91
eISSN - 1521-2254
pISSN - 1099-498X
DOI - 10.1002/jgm.3211
Subject(s) - retinitis pigmentosa , sanger sequencing , compound heterozygosity , genetics , rpe65 , medicine , mutation , ophthalmology , retinal degeneration , biology , retinal , gene , retinal pigment epithelium
Background Retinitis pigmentosa (RP) is one of the most common form of inherited retinal dystrophies. Identification of disease‐causing mutations is a prerequisite for applying targeted therapeutic approaches. The present study aimed to identify disease‐associated mutations in a large Serbian family, in which two brothers have suffered from RP starting in the first decade of their lives. Methods The index patient and 12 additional members of a four‐generation family were analyzed. All participants underwent detailed ophthalmic examinations. Genomic DNA was isolated from family members to perform whole exome sequencing (WES) and Sanger sequencing of candidate genes. Results An early onset RP phenotype was presented in both ocular fundi of the index patient and his brother: arteriolar attenuation, as well as retinal pigmentary changes in peripheral fundus and waxy disc pallor. Both brothers showed foveal thinning. The index patient showed epiretinal membranes in both eyes and a parafoveal cystic lesion in his right eye, whereas the brother of the index patient showed choroid folds and vitreomacular adhesion in his left eye. We identified compound heterozygous mutations in the RPE65 gene (a novel c.1338+1G>A splice donor site mutation in addition to the frame‐shifting mutation c.1207_1210dup (p.Glu404Alafs*4)) using an in‐house WES pipeline. Conclusions Evaluation of all previously described RPE65 mutations showed that the sequence variants identified in the present study located to rarely altered exons and likely effect a highly conserved region of the RPE65 protein. Gene augmentation therapies might be a promising treatment option for the patients described.